<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">
Log In

SmartTRAK Life Sciences News and Analysis Blog

9 min read

DSM Biomedical's Material Contribution to the Wound Care Market - SmartTRAK Interviews Raoul Verheggen

By Susan Paquette on 5/8/19 6:30 PM


SmartTRAK talks with Raoul Verheggen, Global Product Director for DSM Biomedical, regarding the Company’s recent foray into the wound care space and how its addressing unmet needs for patients and businesses

Novel materials and components are key to innovative wound care products that provide superior patient outcomes. DSM Biomedical is a B2B supplier whose business it is to provide these unique components to the medical device industry. SmartTRAK talks with Raoul Verheggen of DSM Biomedical, Global Product Director for Wound, about the company, their capabilities and plans moving forward in support of wound care. A transcript of the interview is below. To listen to the interview recorded via Uberconference, click on the following video. 

Topics: Wound Care
Continue Reading
2 min read

NANS 2019: Highlights and Key Takeaways

By Anne Staylor on 5/7/19 7:30 AM

SmartTRAK highlights key takeaways from the recent North American Neuromodulation (NANS) 22nd annual meeting held in Las Vegas in January, including important company news, trials, technologies, and trends affecting the US market for spinal cord stimulation (SCS) and what's next in this market. This informative article also includes exclusive interviews with leading figures in Neuromodulation including Saluda Medical CEO John Parker, President Abbott Neuromodulation Keith Boetigger, Medtronic Senior VP and Pain Therapies President Marshall Stanton, and Medtronic Senior Global Product Manager for Pain Stimulation and Early Interventions Brian Ranck ...

Continue Reading
3 min read

SmartTRAK's Q418/FY18 Trauma Market Recap

By Natasha Weeks on 5/1/19 1:07 PM

Sequential improvement despite tough comps, supply disruption and pricing pressure

Topics: Orthopedics
Continue Reading
1 min read

SmartTRAK’s Elise Wolf Provides Robotics Expertise at ODT Forum

By Sharon O'Reilly on 4/29/19 2:00 PM



BioMedGPS’s SmartTRAK Senior Analyst for Computer-Assisted Surgery, Elise Wolf, participated as an expert on robotics in a panel discussion entitled “Tech Talk: An Overview of the Growing Role of Additive Manufacturing and Robotic Surgery” at the ODT Forum (Orthopedics Device & Technology Forum) in Memphis, TN on April 11th. The panel, facilitated by Dawn Lissy, President of Empirical Testing, also included spine robotics entrepreneur Mitch Foster, CEO of Mindset Medical and former CEO of Excelsius Surgical, a surgical robotics technology company that was acquired by Globus Medical in 2013. Brian McLaughlin, CEO of Amplify, an additive manufacturing startup specializing in foot and ankle implants, and Chuck Hansford, Director of Advanced Materials Processing at Tecomet, participated in the discussion on additive manufacturing...

Topics: Orthopedics
Continue Reading
3 min read

Q418/FY18 Soft Tissue Fixation Market Recap

By Kristina Meyer on 4/29/19 11:29 AM

The top Sports Medicine competitors are making moves

The consolidation within the Sports Medicine market over the past four years has allowed several of the top players to build upon their growing portfolio and make moves within the market.  While Arthrex continues to lead with innovation, Smith and Nephew is focused on the healing capabilities within its shoulder portfolio.  New-ish CEO Namal Nawana has set the tone of acquisitions across all of SNN’s franchises to enhance SNN’s portfolio and fill gaps in their bag. Stryker is reaping the benefits of their acquisitions and becoming a viable competitor in the hip arthroscopy market.  Zimmer Biomet and CONMED appear to be making a comeback in the Sports market with strong leadership, consistency and a launch into new areas of Sports Medicine...

Among the many topics covered in the Q418/FY18 Soft Tissue FixationMarket Recap are:

Topics: Orthopedics
Continue Reading
2 min read

SAWC Fall 2018: Novel Compression Garment for Complex Edema

By Susan Paquette on 4/24/19 10:00 AM

SmartTRAK highlights the latest research on Sigvaris SECURE presented at SAWC Fall

A novel hybrid compression garment offers promise for patients with difficult-to-treat chronic edema according to an 11-patient case series presented at SAWC Fall. Patients with chronic edema, including lymphedema, are challenged in finding compression garments that are clinically efficacious, cosmetically appealing and comfortable to wear. The 11-patient case series evaluated Sigvaris’ recently launched SECURE, an innovative new Compression and Containment Hybrid (CCH) garment that combines the comfort of circular knit garments and the stiffness traditionally provided by thicker textiles, inelastic wraps or flat knit garments. The new hybrid circular knit garments are thin, cosmetically appealing, and meet the clinical requirement of chronic edema management – graduated compression and containment.

Topics: Wound Care
Continue Reading
3 min read

Q418/FY18 Advanced Wound Care Market Recap

By Susan Paquette on 4/18/19 9:30 AM

Dressings recover Q418, all segments showing solid gains

For FY18, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics were up +4.1% YoY. Acelity remains the global market leader followed by S&N and Mölnlycke. Advanced Dressings, the workhorse of Advanced Wound Care, accounts for 52.3% of WW revenues, up +3.3% YoY. Skin/Dermal Substitute (CTP) revenue was up +10.7% YoY, lower than previous years, but still double-digit gains. WW NPWT was up +4.3% YoY, with traditional devices having a slight uptick and single-use driving the increase of +28.9%.

Among the many topics covered in the Q418/FY18 Advanced Wound Care Market Recap are:

Topics: Wound Care
Continue Reading
1 min read

S&N Solidifies its Leadership Position in Wound Biologics

By Susan Paquette on 4/15/19 12:00 PM

S&N plans to shore up its Advanced Wound Bioactives business with the acquisition of Osiris Therapeutics but the deal may be in question as Osiris shareholders challenge the price.

 Smith & Nephew (S&N) announced on March 12, 2019 that it has agreed to acquire Osiris Therapeutics for $660MM with the deal expected to close Q219. However, the deal could be in question as a group of Osiris shareholders is suing to block the acquisition. The lawsuit disputes Cantor Fitzgerald’s discounted cash flow analysis, saying it does not adequately reflect Osiris’s future growth prospects, and is based on growth rates that are about half of what Osiris has experienced in recent years, resulting in a valuation that is too low. The acquisition would add the Osiris’s Grafix and Stravix product lines to S&N’s ailing Advanced Wound Bioactives portfolio. If allowed to proceed, the acquisition would solidify S&N’s leadership in wound biologics and changes the competitive landscape in the Advanced Wound Care market.

Topics: Wound Care
Continue Reading
3 min read

Q418/FY18 Market Recap: US Hemostats and Sealants

By Doug Devens on 4/9/19 1:39 PM

The US market for Hemostats and Sealants accelerated in Q418 driven by growth in fibrin sealants and thrombin hemostats, overcoming slow growth during the first half of the year.

The US market for Hemostats and Sealants accelerated with +9.3% YoY growth in Q418, continuing to build on its +7.9% YoY in Q318, with fibrin sealants and thrombin hemostats driving the increase. The US market grew +6.1% in FY18, overcoming slow growth during the first half of the year.

As reported in SmartTRAK Financial Dashboard, every manufacturer in the Hemostats and Sealants market, except Pfizer and CryoLife, experienced revenue growth in Q418. Leading the way was Baxter with +33.1% YoY growth as it made progress with its integration of the Mallinckrodt portfolio. Ethicon and Becton Dickinson (BD) both posted solid gains, with +8.7% YoY and +6.6% YoY growth, respectively...

Topics: Wound Care
Continue Reading
5 min read

Q418/FY18 Market Recap: SCS Market Slows

By Anne Staylor on 4/9/19 10:12 AM

The Spinal Cord Stimulation (SCS) market saw high-teens growth in FY18, but decelerated in Q418.

The US SCS Market saw another banner year in FY18, growing +17.4% YoY. Market growth was driven by new product launches, expanding indications and ongoing demand for non-narcotic alternatives that address chronic intractable pain and the opioid epidemic.

Continue Reading
  • There are no suggestions because the search field is empty.

Recent Articles